Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The high mortality attributable to persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in spite of glycopeptide treatment has heightened the need for early detection and intervention with alternative agents. The purpose of this study was to determine the clinical characteristics of and risk factors for persistent MRSA bacteremia. Methods: All first episodes of significant MRSA bacteremia at a 710-bed academic medical center from November 2009 through August 2010 were recorded. Blood cultures were conducted at 3 days and every 2 to 3 days thereafter until clearance. Clinical characteristics and outcomes were compared between persistent MRSA bacteremia (≥ 7 days) and nonpersistent MRSA bacteremia (≤ 3 days). Results: Of 79 patients with MRSA bacteremia during the study period, 31 (39.2%)had persistent MRSA bacteremia. The persistent MRSA bacteremia group had significantly higher 30-day mortality than the nonpersistent MRSA bacteremia group (58.1% vs. 16.7%, p < 0.001). Multivariate analysis indicated that metastatic infection at presentation (odds ratio [OR], 14.57; 95% confidence interval [CI], 3.52to 60.34; p < 0.001) and delayed catheter removal in catheter-related infection (OR,3.80; 95% CI, 1.04 to 13.88; p = 0.004) were independent predictors of persistent MRSA bacteremia. Patients with a time to blood culture positivity (TTP) of < 11.8hours were at increased risk of persistent MRSA bacteremia (29.0% vs. 8.3%, p =0.029). Conclusions: High mortality in patients with persistent MRSA bacteremia was noted. Early detection of metastatic infection and early removal of infected intravascular catheters should be considered to reduce the risk of persistent MRSA bacteremia. Further studies are needed to evaluate the role of TTP for predicting persistent MRSA bacteremia.
Abstract
Background/Aims: The high mortality attributable to persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in spite of glycopeptide treatment has heightened the need for early detection and intervention with alternative agents. The purpose of this study was to determine the clinical characteristics of and risk factors for persistent MRSA bacteremia. Methods: All first episodes of significant MRSA bacteremia at a 710-bed academic medical center from November 2009 through August 2010 were recorded. Blood cultures were conducted at 3 days and every 2 to 3 days thereafter until clearance. Clinical characteristics and outcomes were compared between persistent MRSA bacteremia (≥ 7 days) and nonpersistent MRSA bacteremia (≤ 3 days). Results: Of 79 patients with MRSA bacteremia during the study period, 31 (39.2%)had persistent MRSA bacteremia. The persistent MRSA bacteremia group had significantly higher 30-day mortality than the nonpersistent MRSA bacteremia group (58.1% vs. 16.7%, p < 0.001). Multivariate analysis indicated that metastatic infection at presentation (odds ratio [OR], 14.57; 95% confidence interval [CI], 3.52to 60.34; p < 0.001) and delayed catheter removal in catheter-related infection (OR,3.80; 95% CI, 1.04 to 13.88; p = 0.004) were independent predictors of persistent MRSA bacteremia. Patients with a time to blood culture positivity (TTP) of < 11.8hours were at increased risk of persistent MRSA bacteremia (29.0% vs. 8.3%, p =0.029). Conclusions: High mortality in patients with persistent MRSA bacteremia was noted. Early detection of metastatic infection and early removal of infected intravascular catheters should be considered to reduce the risk of persistent MRSA bacteremia. Further studies are needed to evaluate the role of TTP for predicting persistent MRSA bacteremia.
참고문헌 (32)
- Soriano A, "Pathogenic signif icance of methicillin resistance for patients with Staphylococcus aureus bacteremia", Clin Infect Dis, 30, pp.368~373 (2000)
- Blot SI, "Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus", Arch Intern Med, 162, pp.2229~2235 (2002)
- Jensen AG, "Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases", Arch Intern Med, 162, pp.25~32 (2002)
- Styers D, "Laboratory- based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States", Ann Clin Microbiol Antimicrob, 5, pp.2~ (2006)
- Hawkins C, "Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes", Arch Intern Med, 167, pp.1861~1867 (2007)
- Khatib R, "Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time", Scand J Infect Dis, 41, pp.4~9 (2009)
- Yoon YK, "Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin", J Antimicrob Chemother, 65, pp.1015~1018 (2010)
- Neuner EA, "Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia", Diagn Microbiol Infect Dis, 67, pp.228~233 (2010)
- Fowler VG Jr, "Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein", J Infect Dis, 190, pp.1140~1149 (2004)
- Moise PA, "Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia", Antimicrob Agents Chemother, 51, pp.2582~2586 (2007)
- Lin SH, "Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan", J Antimicrob Chemother, 65, pp.1792~1798 (2010)
- 김재석, "국내 13개 의료기관에서 수집된 Staphylococcus aureus의 항균제 감수성 양상", Annals of Laboratory Medicine, 24(4), pp.223~229 (2004), 대한진단검사의학회
- Kang CI, "stratified analysis according to underlying diseases", J Infect, 61, pp.299~306 (2010)
- Libman H, "Complications associated with Staphylococcus aureus bacteremia", Arch Intern Med, 144, pp.541~545 (1984)
- Li JS, "Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis", Clin Infect Dis, 30, pp.633~638 (2000)
- Sakoulas G, "Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia", J Clin Microbiol, 42, pp.2398~2402 (2004)
- Soriano A, "Inf luence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia", Clin Infect Dis, 46, pp.193~200 (2008)
- Hidayat LK, "High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity", Arch Intern Med, 166, pp.2138~2144 (2006)
- Fowler VG Jr, "Risk factors for hematogenous complications of intravascular catheter- associated Staphylococcus aureus bacteremia", Clin Infect Dis, 40, pp.695~703 (2005)
- Khatib R, "Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection", Clin Infect Dis, 41, pp.594~598 (2005)
- Blot F, "Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis", J Clin Microbiol, 36, pp.105~109 (1998)
- Rogers MS, "The use of continuous monitoring blood culture systems in the diagnosis of catheter related sepsis", J Clin Pathol, 51, pp.635~637 (1998)
- Marra AR, "Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection", J Clin Microbiol, 44, pp.1342~1346 (2006)
- LaPlante KL, "Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model", Antimicrob Agents Chemother, 48, pp.4665~4672 (2004)
- Rybak MJ, "Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists", Clin Infect Dis, 49, pp.325~327 (2009)
- Mason EO, "Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005", J Clin Microbiol, 47, pp.1628~1630 (2005)
- Price J, "Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin", Clin Infect Dis, 48, pp.997~998 (2009)
- Khosrovaneh A, "Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin- resistant Staphylococcus aureus bacteremia", Clin Infect Dis, 38, pp.1328~1330 (2004)
- van Hal SJ, "Methicillin- resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns", J Antimicrob Chemother, 66, pp.2284~2287 (2011)
- Charles PG, "Clinical features associated with bacte remia due to heterogeneous vancomycin-intermediate Staphylococcus aureus", Clin Infect Dis, 38, pp.448~451 (2004)
- Musta AC, "Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years", J Clin Microbiol, 47, pp.1640~1644 (2009)
- Lodise TP, "Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin", Antimicrob Agents Chemother, 52, pp.3315~3320 (2008)